{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:11:08Z","timestamp":1751688668560},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,9,15]]},"DOI":"10.2169\/internalmedicine.1283-22","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T22:11:58Z","timestamp":1673734318000},"page":"2693-2698","source":"Crossref","is-referenced-by-count":3,"title":["Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib"],"prefix":"10.2169","volume":"62","author":[{"given":"Hiroyuki","family":"Arai","sequence":"first","affiliation":[{"name":"Department of Nephrology, Kyoto University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kyoto University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kyoto University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kyoto University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tochio","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kyoto University Graduate School of Medicine, Japan"},{"name":"Department of Nephrology, Japanese Red Cross Society Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Mii","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Analytic Human Pathology, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Minamiguchi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kyoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Muso","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Kitano Hospital, Japan"},{"name":"Department of Food and Nutrition, Faculty of Contemporary Home Economics, Kyoto Kacho University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kyoto University Graduate School of Medicine, Japan"},{"name":"Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30: 187-200, 2019.","DOI":"10.1681\/ASN.2018080853"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367: 2075-2088, 2012.","DOI":"10.1056\/NEJMoa1205127"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132: 393-404, 2018.","DOI":"10.1182\/blood-2016-09-739086"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tan FH, Putoczki TL, Stylli SS, Luwor RB. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. Onco Targets Ther 12: 635-645, 2019.","DOI":"10.2147\/OTT.S189391"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review. Kidney Int Rep 2: 108-123, 2017.","DOI":"10.1016\/j.ekir.2016.09.055"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chan O, Talati C, Isenalumhe L, et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv 4: 530-538, 2020.","DOI":"10.1182\/bloodadvances.2019000268"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 17: 612-621, 2016.","DOI":"10.1016\/S1470-2045(16)00080-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369: 1783-1796, 2013.","DOI":"10.1056\/NEJMoa1306494"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Furuto Y, Hashimoto H, Namikawa A, et al. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report. BMC Nephrol 19: 273, 2018.","DOI":"10.1186\/s12882-018-1074-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ruebner RL, Copelovitch L, Evageliou NF, Denburg MR, Belasco JB, Kaplan BS. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol 29: 863-869, 2014.","DOI":"10.1007\/s00467-013-2696-0"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Izzedine H, Escudier B, Lhomme C, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore) 93: 333-339, 2014.","DOI":"10.1097\/MD.0000000000000207"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Carneiro BA, Kaplan JB, Giles FJ. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events. Expert Rev Hematol 8: 457-479, 2015.","DOI":"10.1586\/17474086.2015.1041910"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int 80: 1271-1277, 2011.","DOI":"10.1038\/ki.2011.288"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Simon M, Gr\u00f6ne HJ, J\u00f6hren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 268: F240-F250, 1995.","DOI":"10.1152\/ajprenal.1995.268.2.F240"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716, 2003.","DOI":"10.1172\/JCI17423"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Dimke H, Sparks MA, Thomson BR, Frische S, Coffman TM, Quaggin SE. Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney. J Am Soc Nephrol 26: 1027-1038, 2015.","DOI":"10.1681\/ASN.2014010060"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sison K, Eremina V, Baelde H, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 21: 1691-1701, 2010.","DOI":"10.1681\/ASN.2010030295"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136, 2008.","DOI":"10.1056\/NEJMoa0707330"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Guan F, Villegas G, Teichman J, Mundel P, Tufro A. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 291: F422-F428, 2006.","DOI":"10.1152\/ajprenal.00448.2005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Veron D, Reidy KJ, Bertuccio C, et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 77: 989-999, 2010.","DOI":"10.1038\/ki.2010.64"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fogo AB. Talking back: the podocytes and endothelial cells duke it out. Kidney Int 90: 1157-1159, 2016.","DOI":"10.1016\/j.kint.2016.08.031"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, Selgas R. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant 25: 1001-1003, 2010.","DOI":"10.1093\/ndt\/gfp666"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol 16: 310-315, 2012.","DOI":"10.1007\/s10157-011-0543-9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Buob D, Decambron M, Gnemmi V, et al. Collapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney. Kidney Int 90: 1321-1331, 2016.","DOI":"10.1016\/j.kint.2016.07.021"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kobayashi N, Ueno T, Ohashi K, et al. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated \u03b21-integrin endocytosis. Am J Physiol Renal Physiol 308: F614-F626, 2015.","DOI":"10.1152\/ajprenal.00616.2014"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mahtal N, Lenoir O, Tharaux PL. Glomerular endothelial cell crosstalk with podocytes in diabetic kidney disease. Front Med (Lausanne) 8: 659013, 2021.","DOI":"10.3389\/fmed.2021.659013"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Collino F, Bussolati B, Gerbaudo E, et al. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 294: F1185-F1194, 2008.","DOI":"10.1152\/ajprenal.00442.2007"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Craici IM, Wagner SJ, Weissgerber TL, Grande JP, Garovic VD. Advances in the pathophysiology of pre-eclampsia and related podocyte injury. Kidney Int 86: 275-285, 2014.","DOI":"10.1038\/ki.2014.17"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/18\/62_1283-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:28:52Z","timestamp":1715574532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/18\/62_1283-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":28,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1283-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"article-number":"1283-22"}}